INTRODUCTION AND OBJECTIVES: Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer associated with poor survival rates. In CRPC, 84% of patients have metastases and the survival rate is 28% despite improvements in treatment options. We have shown that PCSD1, a well-characterized xenograft derived from a human prostate cancer right femoral metastasis, is resistant to the anti-androgen drug, bicalutamide, specifically in the bone niche, replicating the donor patient. To understand the mechanisms of resistance to androgen deprivation therapy (ADT) in the bone, we treated PCSD1 and PCSD13, a novel patient derived xenograft model from a different patient's anaplastic prostate cancer femoral metastasis with the anti-androgen, enzalutamide.
METHODS: PCSD1 cells stably transduced with GFPLuciferase were transplanted into male Rag2-/-gammac-/-mice intrafemorally (IF) or subcutaneously (SC). Four weeks post SC or IF injection, mice with established tumors were treated with enzalutamide (10mg/kg/day) or vehicle control for 35 days (SC) or 30 days (IF). Tumor growth was measured bi-weekly with calipers and in vivo bioluminescence (IVIS). Similarly, PCSD13 cells were injected into femurs of male Rag2-/-gammac-/-mice. Eight weeks post IF injection, mice were treated with Enzalutamide or Vehicle for 50 days. Tumor growth was measured bi-weekly with calipers. FACS, single cell RNASeq, deep RNASeq were performed on tumors. PSA was measured via qPCR and immunohistochemistry.
RESULTS: Enzalutamide completely inhibited growth and led to regression of sub-cutaneous PCSD1 tumors. In contrast, enzalutamide treatment only partially reduced tumor growth of intrafemoral PCSD1 and PCSD13 xenografts. Re-injection of ENZAresistant PCSD1 intra-femoral tumor cells as sub-cutaneous tumors showed that some retained their ENZA resistance while others regained ENZA-sensitivity. Transcriptomic analyses revealed significant upregulation of WNT5A, EMT and neuronal programs. Single cell analyses revealed heterogeneous sub-populations that behaved as cancer stem cells in 3D/organoid cultures. CONCLUSIONS: Our patient derived xenograft models demonstrate that the bone niche promotes tumor growth even when treated with anti-androgen. Tumor growth is inhibited when injected subcutaneously, resembling the effectiveness of androgen deprivation therapy toward localized prostate cancer. This elucidates the importance of utilizing in vivo patient derived models to gain a better understanding of why the bone niche supports tumor growth.
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Tobias Lange, Su Jung Oh-Hohenhorst*, Simon Joosse, Hamburg, Germany; Oliver Hahn, Goettingen, Germany; Tobias Gosau, Susanne Feldhaus, Hanna Maar, Renate Gehrcke, Martina Kluth, Ronald Simon, Thorsten Schlomm, Hartwig Huland, Udo Schumacher, Hamburg, Germany INTRODUCTION AND OBJECTIVES: A major limitation in PCa research is the lack of relevant preclinical models, which allow studying various aspects of metastatic PCa. Here, we established a novel PDX model reflecting the pathophysiology of metastatic human CRPC.
METHODS: PCa tissue for the PDX model was obtained from a patient with high-risk PCa (Gleason 5þ4 in 12 of 12 cores) during radical prostatectomy and plugged directly into the immunecompromised SCID Balb/c mouse. The tumors were subsequently transplanted in vivo by mouse-to-mouse passages. DNA from the blood and distant organs of these mice were isolated for quantification of metastatic cell loads upon serial transplantation by Alu-PCR.
Expression of AR, PSMA and ERG in primary tumors and corresponding lung tissue were detected by IH, while PTEN and CHD1 status were analysed by FISH.
To identify genomic and transcriptomic alterations DNA and RNA from primary tumors were isolated for Next Generation Sequencing and RNA sequencing respectively. In vitro cultivation of the cells was performed by two-or three-dimensional growth conditions in the presence or absence of androgen and antiandrogen.
RESULTS: The established PDX model was termed "C5". Clinical features of the C5 donor were characterized by limited or no response to the neoadjuvant and adjuvant ADT, rapid disease progression by metastasis and primary resistance to abiraterone.
The initial transplanted C5 PDX tumor grew within 207 days (d) resulting subcutaneous primary tumor and micro distant metastasis in bone marrow. Afterwards, the tumor growth periods were much shorter and ranged from 62 to 122 d. The tumors could be serially transplanted between mice and grew within w90 d to 1.5-2 cm³ tumors in SCID Balb/c mice (take rate 100 %), NOD-scid IL2Rgnull (NSG) mice (100 %) and C57BL/6 pfp-/-/rag2-/-mice (66%). There was no tumor growth in female mice. C5 tumors maintained the key characteristics of the original tumor for at least 6 passages and were ARþ, PSMAþ, ERGþ, PTEN-/-, CHD1AE. Upon serial transplantation, some C5 tumors spontaneously disseminated to distant sites with a trend towards higher metastatic cell loads. Lung metastases exclusively demonstrated single DTC and micrometastases. Whole genome sequencing and whole exome sequencing data of C5 demonstrated the copy number aberration/ mutation status of this model proving genomic stability over several passages. Moreover, we observed genomic and transcriptomic alterations during metastatic progression achieved by serial transplantation. The C5 tumors could be cryopreserved and showed normal growth characteristics in vivo afterwards. C5 tumor cells did not grow stably in vitro.
CONCLUSIONS: This novel PCa PDX model C5 will enable future research on several aspects of metastatic CRPC, particularly for the ARþ, ERGþ, PTEN-/-PCa subtypes. is the 3rd most prevalent type of cancer behind breast and lung cancer, with >220,000 new cases arising per year in the United States. The 5-year survival rate for prostate cancer is >98%, but patients that have undergone androgen deprivation therapy (ADT) to treat advanced prostate cancer will develop castration resistant prostate cancer (CRPC) in 10-20% of cases, with survival rates dropping to 29%. The purpose of this study was to investigate the role of increasing FGF5 expression in the progression of PRCA.
METHODS: Utilizing the LNCaP series and the BCaP cell line model of prostate cancer progression, we assessed FGF5 expression and function in vitro. Overexpression plasmids and recombinant FGF5 (rFGF5) were used for gain of function (GOF) studies, while siRNA was used for loss of function. We used a progression tissue microarray (pTMA) to assess FGF5 expression in a clinical context (n[384) .
RESULTS: GOF experiments revealed that FGF5 significantly increases the expression of androgen receptor (AR) mRNA and protein. In addition, FGF5 was found to induce nuclear localization and activation of AR in the absence of ligand, suggesting ligand-independent activation of AR by FGF5. Conversely, when FGF5 was inhibited using siRNA in a cell line expressing high levels of AR mRNA and FGF5, AR mRNA was significantly decreased.
When androgen-dependent LNCaP cells were subjected to an androgen-depleted environment, to mimic ADT, FGF5 protein and mRNA significantly increased. Additionally, when AR was stimulated using androgen, FGF5 protein and mRNA levels significantly decreased. These effects are not observed in cell lines that do not express AR or are AR-independent suggesting AR is directly regulating FGF5. Finally, in the BCaP model there was a significant increase in the mRNA and protein expression of FGF5 in tumorigenic cell lines compared to nontumorigenic. TMA analysis of clinical samples revealed a significant increase in FGF5-positive cells across progression of prostate cancer from benign to metastatic.
CONCLUSIONS: To our knowledge, this is the first characterization of the expression and role of FGF5 in the prostate. Our results suggest that the increase in FGF5 expression in PRCA progression could lead to an increase in AR over time, and that this increase in FGF5 could be induced in men on ADT. The mechanism of how FGF5 increases AR will be investigated next, as this could be implicated in the emergence of CRPC following ADT.
